LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

43.47 0.98

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.06

Max

43.84

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+30.58% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	71M 3.3B
Eelmine avamishind	42.49
Eelmine sulgemishind	43.47

Uudiste sentiment

By Acuity

50%

154 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. märts 2026, 23:35 UTC

Uudisväärsed sündmused

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1. märts 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1. märts 2026, 23:19 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1. märts 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1. märts 2026, 22:55 UTC

Uudisväärsed sündmused

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1. märts 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1. märts 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1. märts 2026, 22:38 UTC

Market Talk

Uudisväärsed sündmused

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1. märts 2026, 22:21 UTC

Tulu

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1. märts 2026, 22:17 UTC

Market Talk

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1. märts 2026, 22:00 UTC

Market Talk

Uudisväärsed sündmused

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1. märts 2026, 21:40 UTC

Market Talk

Uudisväärsed sündmused

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1. märts 2026, 21:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1. märts 2026, 21:30 UTC

Market Talk

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1. märts 2026, 21:27 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1. märts 2026, 21:19 UTC

Market Talk

Uudisväärsed sündmused

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1. märts 2026, 20:58 UTC

Market Talk

Uudisväärsed sündmused

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1. märts 2026, 20:40 UTC

Market Talk

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1. märts 2026, 20:24 UTC

Market Talk

Uudisväärsed sündmused

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

30.58% tõus

12 kuu keskmine prognoos

Keskmine 56.45 USD 30.58%

Kõrge 66 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

154 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.